Find out about our work

GloPID-R brings together funding bodies investing in research related to new or re-emerging infectious diseases. Our aim is to ensure that research capacity and capabilities are in place to support the rapid initiation of scientific research in case of an outbreak.

Mapping capacities and identifying bottlenecks

GloPID-R conducted a Connecting and Mapping Study to explore the capacities and capabilities of both research networks and funders to respond to outbreaks of pandemic potential. The report also explores the PEARLES (political, ethical, administrative, regulatory, logistical, economic, and social) barriers to rapid pandemic research in greater detail.

ZIKA outbreak response

On the same day as PAHO’s epidemiological alert (December 1, 2015) GloPID-R initiated its response to the Zika outbreak. Working groups were rapidly formed to address issues related to aetiology, vaccines, diagnostics and vector control. Their findings are available in the report, Ongoing and Upcoming Research on the Zika Virus. This regularly updated document identifies experts, research capacities in the field of ZIKV and key research questions. See also Zika Outbreak for a complete list of actions.

Response plan

A response plan is being developed, based on GloPID-R’s experience with the Zika epidemic. It will define the triggers for a rapid research response, provide the steps for identifying research needs during an outbreak and describe the mechanism for coordination among research funders.

Response Plan Working Group

  • Chair: Line Matthiessen, European Commission (EC)
  • Serge Desnoyers, Canadian Institutes of Health Research (CIHR), Canada
  • Eric D’Ortenzio, Institut National de la Santé et de la Recherche Médicale (INSERM), France
  • Jeannette Endres-Becker, German Federal Ministry for Education and Research (BMBF), Germany
  • Finnian Hanrahan, European Commission (EC)
  • Anne Kelso, National Health and Medical Research Council, Australia
  • Marion Koopmans, GloPID-R Scientific Advisory Board
  • Åse-Marit Kristiansen, Research Council of Norway (RCN), Norway
  • Kajsa-Stina Longuere, GloPID-R Secretariat
  • Man-Seong Park, National Research Foundation of Korea, Seoul National University, South Korea
  • Fabien Quintard, GloPID-R Secretariat
  • Carlos Segovia, Instituto de Salud Carlos III, Spain
  • Mike Turner, Wellcome Trust, UK
  • Brian Ward, GloPID-R Scientific Advisory Board
  • Yazdan Yazdanpanah, GloPID-R Scientific Advisory Board

Data-sharing

A framework is being developed as a basis for sharing data during public health emergencies. The data to be considered includes surveillance data, clinical trial data, pathogen genome data, case reports and results derived from this data. An action plan will be drawn up by the working group to identify areas where progress can be made quickly.

Data Sharing Working Group

  • Chair: Katherine Littler, Wellcome Trust, UK
  • Sophie Mathewson, Wellcome Trust, UK
  • Wee-Ming Boon, National Health and Medical Research Council, Australia
  • Alison Bourgon, International Development Research Centre (IDRC), Canada
  • Gail Carson, GloPID-R Secretariat
  • Evelyn Depoortere, European Commission
  • Jeannette Endres-Becker, German Federal Ministry for Education and Research (BMBF), Germany
  • Matthew Garsia, Canadian Institutes of Health Research
  • Gaetano Gugliemi, Ministry of Health, Italy
  • Gun Peggy Knudsen, Norwegian Institute of Public Health, Norway
  • Kajsa-Stina Longuere, GloPID-R Secretariat
  • France Mentre, Institut National de la Santé et de la Recherche Médicale (INSERM), France
  • Daniel Mietchen, National Institutes of Health, USA
  • Farah Al-Shorbaji, World Health Organization (WHO)
  • Vasee Moorthy, World Health Organization (WHO)
  • Jeffrey Mphahlele, South African Medical Research Council (SA MRC), South Africa
  • Denise O’Connor, European Commission
  • Carlos Segovia, Instituto de Salud Carlos III, Spain
  • Seung-Hyeok Seok, National Research Foundation of Korea, Seoul National University, South Korea

yellow Fever

GloPID-R also mobilized its members to discuss the Yellow Fever outbreak in Angola and several other African countries where there was a risk of a temporary shortage of available vaccines. It developed a working group to identify research gaps and possible priorities.

Yellow Fever Working Group

  • Chair: Josie Golding, Wellcome Trust, UK
  • Philip Bejon, Wellcome Trust, UK
  • Moses Bockaire, European & Developing Countries Clinical Trials Partnership (EDCTP)
  • Rafael de Andres Medina, Instituto de Salud Carlos III, Spain
  • Jean-François Delfraissey, Institut National de la Santé et de la Recherche Médicale (INSERM), France
  • Evelyn Depoortere, European Commission
  • Gary Disbrow, US Department of Health and Human Services, USA
  • Joachim Hombach, World Health Organization (WHO)
  • Michael Kurilla, National Institutes of Health (NIH), USA
  • Philip Lambach, World Health Organization (WHO)
  • Chris Lewis, UK Department for International Development (DFID), UK
  • Tina Lorenson, Bill & Melinda Gates Foundation (BMGF), USA
  • Nicole Lurie, US Department of Health and Human, USA
  • Line Matthiessen, European Commission
  • Bernadette Murge, World Health Organization (WHO)
  • Juan Riese, Instituto de Salud Carlos III, Spain
  • Cathy Roth, UK Department for International Development (DFID), UK
  • Erin Staples, Centers for Disease Control and Prevention (CDC), USA
  • Yazdan Yazdanpanah, Institut National de la Santé et de la Recherche Médicale (INSERM), France